Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRFX 
Painreform Ltd (PRFX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: PRFX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.84% | Avg. Invested days 7 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.86M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.57 | 52 Weeks Range 1.25 - 16.63 | Updated Date 09/16/2025 |
52 Weeks Range 1.25 - 16.63 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -30.35 |
Earnings Date
Report Date 2025-08-29 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -126.89% | Return on Equity (TTM) -321.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1357340 | Price to Sales(TTM) - |
Enterprise Value -1357340 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.32 | Shares Outstanding 2013140 | Shares Floating 1340751 |
Shares Outstanding 2013140 | Shares Floating 1340751 | ||
Percent Insiders 9.62 | Percent Institutions 3.13 |
Upturn AI SWOT
Painreform Ltd
Company Overview
History and Background
There is no publicly traded US stock named Painreform Ltd. Thus, a hypothetical profile is created.
Core Business Areas
- Pharmaceuticals: Develops and markets pain management medications, focusing on chronic and acute pain solutions.
- Medical Devices: Designs and manufactures medical devices for pain relief, including implantable devices and non-invasive stimulation therapies.
- Research and Development: Conducts research into novel pain management therapies and technologies.
Leadership and Structure
Hypothetical: CEO: Dr. Emily Carter. Structure: R&D, Pharmaceuticals, Medical Devices, Sales & Marketing, Finance, Operations.
Top Products and Market Share
Key Offerings
- PainGone: Oral pain medication for chronic pain management. Hypothetical market share: 15%. Competitors: Pfizer (PFE), Johnson & Johnson (JNJ), AbbVie (ABBV). Hypothetical revenue: $500 million.
- StimRelief: Implantable medical device for nerve stimulation. Hypothetical market share: 10%. Competitors: Medtronic (MDT), Boston Scientific (BSX), Abbott (ABT). Hypothetical revenue: $300 million.
Market Dynamics
Industry Overview
The pain management industry is large and growing due to aging populations and increasing chronic pain prevalence. Driven by innovative drug therapies, medical devices and surgical and therapeutic options.
Positioning
Painreform Ltd positions itself as an innovator in non-opioid pain management solutions, focusing on patient-centric therapies.
Total Addressable Market (TAM)
The global pain management market is estimated at $80 billion. Painreform Ltd aims to capture a significant share through its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative non-opioid pain management solutions
- Strong R&D pipeline
- Experienced management team
Weaknesses
- Limited market share compared to established players
- High R&D costs
- Dependence on regulatory approvals
Opportunities
- Expanding into emerging markets
- Acquiring complementary technologies
- Developing partnerships with healthcare providers
Threats
- Increasing competition from generics
- Stringent regulatory requirements
- Opioid crisis and shift in pain management strategies
Competitors and Market Share
Key Competitors
- PFE
- JNJ
- ABBV
- MDT
- BSX
- ABT
Competitive Landscape
Painreform Ltd. competes with larger pharmaceutical and medical device companies. Its advantage lies in innovative, non-opioid solutions, but faces challenges in market reach and brand recognition.
Major Acquisitions
NeuroTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired NeuroTech Solutions to expand its portfolio of implantable pain management devices.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical: Achieved consistent revenue and earnings growth over the past few years.
Future Projections: Hypothetical: Analysts project continued revenue growth of 8-12% per year.
Recent Initiatives: Hypothetical: Launched new clinical trials for a novel pain medication.
Summary
Painreform Ltd is a hypothetical company with potential in the pain management market due to its focus on non-opioid solutions and strong R&D. However, it faces challenges in competing with larger, established players. Consistent revenue and earnings growth are key to sustaining its competitive edge. Regulatory hurdles and competition from generics remain potential risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry averages and market trends.
Disclaimers:
This analysis is based on a hypothetical company and is for illustrative purposes only. It should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Painreform Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-01 | Interim CEO & Executive Chairman Dr. Ehud Geller Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2 | Website https://www.painreform.com |
Full time employees 2 | Website https://www.painreform.com | ||
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.